冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CHMP 冠军工业

未开盘 12-20 16:00:00 EST 延时

{"stockData":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"冠军工业","latestPrice":0.0001,"timestamp":1734728400000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033405,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"12-20 16:00:00 EST 延时","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033405,"exchange":"EXPERT","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"adjPreClose":0.0001,"adrRate":0,"volumeRatio":2.7777835648268714},"requestUrl":"/m/hq/s/CHMP/wiki","defaultTab":"wiki","newsList":[{"id":"2484564742","title":"一哥的业绩，投资人不买账","url":"https://stock-news.laohu8.com/highlight/detail?id=2484564742","media":"并购菁英汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484564742?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:03","pubTimestamp":1731924185,"startTime":"0","endTime":"0","summary":"按理说，百济神州拳头产品取得强势的增长且公司非GAAP净利润连续第二个季度实现盈利的背景下，公司股价并未像今年二季度业绩公布前后实现市值的显著提升，相反资金却选择了短期内对其进行抛售。显然，百济神州2024Q3费用控制层面让投资者认为有不及预期的地方。尽管百济神州作为海外PD-1市场的后发者，但获批适应症患者数量众多，叠加近日FDA限制已上市部分PD-1在胃癌适应症上的使用，替雷利珠单抗存在一定差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118183602abcc4675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0053666078.USD","CHMP","BK4535","BK4087","L","06160","BK4526","BK4588","BGNE","BK4548","688235","BK4107","BK4505","BK4585","BK4504"],"gpt_icon":0},{"id":"2482705245","title":"摸不准的AD市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2482705245","media":"佰傲谷BioValley","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482705245?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:02","pubTimestamp":1731412920,"startTime":"0","endTime":"0","summary":"刚刚披露的渤健第三季度财报中，两家公司推出的第二款AD药物Leqembi的销售表现还被认为超出市场预期，然而风向一转，Leqembi的销售预期就又被下调了。时隔半年，Leqembi就获得FDA完全批准，成为第一个真正意义上获得FDA认可的AD新药。在去年AD市场上只有这一款Aβ单抗在市销售的情况下，Leqembi总共才卖了1000万美元——远低于市场预期。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-12/doc-incvvkhc6095242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2481688879","title":"BUZZ-Apellis 制药公司第三季度亏损扩大，业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2481688879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481688879?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:42","pubTimestamp":1730817751,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    11月5日 - ** 生物制药公司Apellis Pharmaceuticals   股价下跌8.9%至26.02美元** APLS 以近三个月低点开盘** 该公司公布的第三季度亏损超出预期  ** 第三季度亏损46美分/每小时，预计亏损30美分/每小时 - LSEG ** 公司第三季度实现营业收入 1.968 亿美元，预计为 2.0035 亿美","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CHMP","APLS","BK4139","LU1093756168.USD","LU1093756325.SGD","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"2469679124","title":"BUZZ-欧盟专家组确认对眼疾药物持否定意见，Apellis业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2469679124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469679124?lang=zh_cn&edition=full","pubTime":"2024-09-21 01:01","pubTimestamp":1726851662,"startTime":"0","endTime":"0","summary":" (更新)    9月20日 - ** Apellis制药公司  股价下跌14.3%至31.46美元，创下自2023年8月以来的最低水平 。** Apellis称欧洲药品监管机构的人用医药产品委员会 已确认对其实验性药物培西他克普兰持否定意见** Pegcetacoplan是一种治疗地理性萎缩的试验性药物，地理性萎缩是一种渐进性和不可逆的眼部疾病，是由于病变的生长破坏了负责视力的视网膜细胞而引起的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1093756325.SGD","LU1093756168.USD","CHMP","BK4505","APLS","BK4139","BK4588","BK4087"],"gpt_icon":0},{"id":"2468344646","title":"BUZZ-欧盟专家组确认对眼疾药物持否定意见，Apellis 公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2468344646","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468344646?lang=zh_cn&edition=full","pubTime":"2024-09-20 18:51","pubTimestamp":1726829515,"startTime":"0","endTime":"0","summary":"    9月20日 - ** Apellis制药公司  股价盘前下跌3.7%至35.36美元 ** Apellis称欧洲药品监管机构的人用医药产品委员会 已确认对其实验性药物培西他克普兰持否定意见** Pegcetacoplan是一种治疗地理性萎缩的试验性药物，地理性萎缩是一种渐进性和不可逆的眼病，是由于病变的生长破坏了负责视力的视网膜细胞而引起的。** APLS 于 6 月份寻求重新审查  CHMP 对该药上市申请的负面意见 ** 截至上次收盘，该股累计下跌约 39","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","CHMP","LU1093756325.SGD","BK4087","LU1093756168.USD","BK4588","BK4139","APLS"],"gpt_icon":0},{"id":"2455650549","title":"阿尔兹海默药物Leqembi上市许可遭拒欧洲人用医品委员会(CHMP)建议拒绝授予Leqembi上市许可，理由是存在安全问题，包括涉及脑肿胀和潜在出血的副作用。","url":"https://stock-news.laohu8.com/highlight/detail?id=2455650549","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455650549?lang=zh_cn&edition=full","pubTime":"2024-07-29 10:31","pubTimestamp":1722220260,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B19Z9Z06.USD","BIIB","BK4588","IE00B894F039.SGD","LU0109394709.USD","CHMP","LU0320765992.SGD","BK4532","IE00B19Z9P08.USD","BK4087","BK4139","LU0889565916.HKD","BK4585","BK4533","LU0234570918.USD"],"gpt_icon":0},{"id":"2454543619","title":"君实生物公告，公司产品特瑞普利单抗（欧洲商品名：LOQTORZI®）的上市许可申请获得欧洲药品管理局人用药品委员会（简称“CHMP”）的积极意见，建议批准其用于治疗两项适应症：特瑞普利单抗联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗，以及特瑞普利单抗联合顺铂和紫杉醇用于不可切除的晚期/复发或转移性食管鳞癌成人患者的一线治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454543619","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454543619?lang=zh_cn&edition=full","pubTime":"2024-07-28 16:07","pubTimestamp":1722154042,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1161","688180","BK4087","BK1583","BK1515","CHMP","01877","BK0239"],"gpt_icon":0},{"id":"2454548231","title":"【君实生物(688180.SH)：特瑞普利单抗获欧洲药品管理局人用药品委员会积极意见】智通财经APP讯，君实生物(688180.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454548231","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454548231?lang=zh_cn&edition=full","pubTime":"2024-07-28 15:41","pubTimestamp":1722152472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","BK1161","688180","BK1515","CHMP","BK4087","BK1583","01877"],"gpt_icon":0},{"id":"2454531014","title":"【卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻】智通财经APP获悉，7月26日，卫材(ESALY.US)合作方BioArctic公司宣布欧洲药品管理局(EMA)人用药品委员会(CHMP)不建议批准仑卡奈单抗(Lecanemab)上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454531014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454531014?lang=zh_cn&edition=full","pubTime":"2024-07-27 16:33","pubTimestamp":1722069191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2454053104","title":"卫材(ESALY.US)合作方重磅药仑卡奈单抗欧洲上市遇阻","url":"https://stock-news.laohu8.com/highlight/detail?id=2454053104","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454053104?lang=zh_cn&edition=full","pubTime":"2024-07-27 16:33","pubTimestamp":1722069191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月26日，卫材合作方BioArctic公司宣布欧洲药品管理局人用药品委员会不建议批准仑卡奈单抗上市。当天，BioArctic迅速与卫材进行了沟通，后者表示将与CHMP进行沟通，要求其重新审查给出的负面意见。仑卡奈单抗是BioArctic开发的一种抗β淀粉样蛋白(Aβ)单克隆抗体，可以选择性中和并清除导致阿尔茨海默病神经病变的可溶且有毒性的Aβ聚集体。因此，仑卡奈单抗可能对AD病理过程产生积极影响并减缓疾病发展进程。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2454307720","title":"【安斯泰来(ALPMY.US)CLDN18.2单抗获推荐在欧盟上市】智通财经APP获悉，安斯泰来（Astellas Pharma，ALPMY.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454307720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454307720?lang=zh_cn&edition=full","pubTime":"2024-07-27 08:12","pubTimestamp":1722039136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ALPMY","BK4007","CHMP","BK4087"],"gpt_icon":0},{"id":"2454030793","title":"诺和诺德今天宣布，欧洲药品管理局（EMA）人用药品委员会（CHMP）已采纳积极意见，同意更新其每周一次皮下注射减重疗法Wegovy（2.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454030793","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454030793?lang=zh_cn&edition=full","pubTime":"2024-07-27 08:08","pubTimestamp":1722038912,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1576","BK4532","BK4183","LU2242644610.SGD","BK4585","LU2125910500.SGD","NVO","LU0708995583.HKD","BK4087","BMI","LU0052750758.USD","LU0154236417.USD","BK1583","MACE","02359","LU1093756325.SGD","LU1093756168.USD","BK0216","LU1997245177.USD","603259","IE00BZ1G4Q59.USD","BK4077","LU0456842615.SGD","LU1997245094.SGD","CHMP","LU2045819591.USD","BK4007","IE00BKVL7J92.USD","BK1141","LU1046422090.SGD","BK4588","TCEHY","BK4157","LU0320764599.SGD"],"gpt_icon":0},{"id":"2454373847","title":"欧洲药管局拒绝阿兹海默症明星药上市 发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2454373847","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454373847?lang=zh_cn&edition=full","pubTime":"2024-07-27 01:05","pubTimestamp":1722013501,"startTime":"0","endTime":"0","summary":"　　当地时间周五，欧洲药管局人用药品委员会发布本周新药审议会议的摘要：该委员会建议药管局批准14款新药，扩大11款药物的适应症范围，并建议否决一款药物的上市申请——日本卫材和美国渤健研发和销售的阿兹海默症新药Leqembi。　　投行杰富瑞总结分析称，在欧洲药管局相关药品委员会作出的负面判断中，有接近五分之二的负面裁定最终被推翻。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/162/w550h412/20240727/34fc-4d829f40d46911dc3d277d31b14533ec.png","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/162/w550h412/20240727/34fc-4d829f40d46911dc3d277d31b14533ec.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2024-07-26/doc-incfnvfs1701663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["ARIA","CHMP","BK4087"],"gpt_icon":0},{"id":"2454310053","title":"Eisai公司将寻求重新审查CHMP意见。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454310053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454310053?lang=zh_cn&edition=full","pubTime":"2024-07-26 19:21","pubTimestamp":1721992869,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2454129883","title":"默沙东公司获得欧洲药品监管局肯定性CHMP意见认为Keytruda® (Pembrolizumab)与Padcev® (Enfortumab Vedotin-Ejfv)结合用作不可切除或转移性膀胱癌患者的一线治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2454129883","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454129883?lang=zh_cn&edition=full","pubTime":"2024-07-26 18:50","pubTimestamp":1721991003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BLSP4452.SGD","IE00BN8TJ469.HKD","BK4534","LU1989771016.USD","IE00B1BXHZ80.USD","LU0265550946.USD","LU1061106388.HKD","BK4087","BK4007","LU1934455194.USD","LU0289739699.SGD","IE000M9KFDE8.USD","LU1023059063.AUD","LU1066051811.HKD","BK4533","LU0238689110.USD","LU0058720904.USD","BK4559","LU0965509101.SGD","BK4550","LU1066051498.USD","IE00BBT3K403.USD","LU0265550359.USD","CHMP","BK4516","LU0985320562.USD","LU1974910355.USD","LU0070302665.USD","MRK","LU1291159041.SGD","LU1066051225.USD","LU1037948541.HKD","IE00BJT1NW94.SGD","LU1941712348.USD","LU0266013472.USD","IE00BSNM7G36.USD","LU0234572021.USD","LU0965509010.AUD","LU1585245621.USD","LU1989772840.SGD","LU1057294990.SGD","LU1934455277.USD","LU0211331839.USD","LU1037948897.HKD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0208291251.USD","LU0965508806.USD","IE00BLSP4239.USD","LU0965509283.SGD"],"gpt_icon":0},{"id":"2450324454","title":"全球首款胰岛素周制剂在美遇挫，FDA要求补充信息，今年或无望获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2450324454","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450324454?lang=zh_cn&edition=full","pubTime":"2024-07-12 12:17","pubTimestamp":1720757844,"startTime":"0","endTime":"0","summary":"全球首款胰岛素周制剂在美上市暂遇挫折。诺和诺德正在评估相关内容，并与美国FDA展开密切合作以满足要求，预计今年无法满足这些要求。尽管依柯胰岛素在美获批遇挫，但这一产品已经在欧盟、瑞士、加拿大、澳大利亚等全球多地区获批。今年5月，礼来制药披露了旗下胰岛素周制剂Efsitora的研究进展。这一产品为每周皮下注射给药一次的超长效胰岛素周制剂，适应证为糖尿病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121220559f392c15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407121220559f392c15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","IE00BZ1G4Q59.USD","BK4530","CHMP","BK4007","CRL","BK4585","IE00BKVL7J92.USD","NVO","BK4532","BK4121","LU0390134368.USD","BK4087","LU0154236417.USD"],"gpt_icon":0},{"id":"2448953254","title":"罗氏新一代抗体疗法获积极监管决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2448953254","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448953254?lang=zh_cn&edition=full","pubTime":"2024-07-01 13:01","pubTimestamp":1719810061,"startTime":"0","endTime":"0","summary":"日前，罗氏宣布，欧洲药品管理局的人用药品委员会已对其新一代C5循环抗体Piasky用以治疗阵发性睡眠性血红蛋白尿症采纳了积极意见。该疗法可能为成为当前定期静脉输注C5抑制剂疗法的替代选择，有望帮助减少PNH患者及其照护者的负担和生活干扰。PNH是一种罕见且危及生命的综合征，患者会突然出现血尿、贫血和血栓形成等症状。目前临床上有多款处于临床阶段的在研PNH疗法，期待这些在研疗法能最终顺利获得批准，造福更多PNH患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/01130141292788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2448938148","title":"【罗氏(RHHBY.US)新一代抗体疗法获积极监管决定】智通财经APP获悉，日前，罗氏(Roche/RHHBY.US)宣布，欧洲药品管理局(EMA)的人用药品委员会(CHMP)已对其新一代C5循环抗体Piasky(crovalimab，可伐利单抗)用以治疗阵发性睡眠性血红蛋白尿症(PNH)采纳了积极意见。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448938148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448938148?lang=zh_cn&edition=full","pubTime":"2024-07-01 08:52","pubTimestamp":1719795177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RHHBY","BK4087","CHMP","03165","BK4007"],"gpt_icon":0},{"id":"2446050987","title":"Rhythm Pharmaceuticals获得积极的CHMP意见用于治疗2至6岁、患有Bardet Biedl综合征或Pomc、Pcsk1或Lepr缺陷的肥胖和控制饥饿的患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2446050987","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446050987?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:00","pubTimestamp":1719576022,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2446570983","title":"Apellis计划在欧盟地理性萎缩（GA）pegcetacoplan获得负面CHMP意见后寻求复审。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446570983","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446570983?lang=zh_cn&edition=full","pubTime":"2024-06-28 18:57","pubTimestamp":1719572242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4087","CHMP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.champion-industries.com","stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.0306},{"period":"3month","weight":0.1071},{"period":"6month","weight":0.1071},{"period":"1year","weight":0.069},{"period":"ytd","weight":-0.225}],"description":"2450 First Avenue P.O. Box 2968 Huntington West Virginia","exchange":"EXPERT","name":"冠军工业","nameEN":"Champion Industries, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冠军工业,CHMP,冠军工业股票,冠军工业股票老虎,冠军工业股票老虎国际,冠军工业行情,冠军工业股票行情,冠军工业股价,冠军工业股市,冠军工业股票价格,冠军工业股票交易,冠军工业股票购买,冠军工业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冠军工业(CHMP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冠军工业(CHMP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}